EYLEA (aflibercept) is a recombinant fusion protein
consisting of portions of human VEGF receptors 1 and 2 extracellular domains
fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for
intravitreal administration. Aflibercept is a dimeric glycoprotein with a
protein molecular weight of 97 kilodaltons (kDa) and contains glycosylation,
constituting an additional 15% of the total molecular mass, resulting in a
total molecular weight of 115 kDa. Aflibercept is produced in recombinant
Chinese hamster ovary (CHO) cells.
EYLEA is a sterile, clear, and colorless to pale yellow
solution. EYLEA is supplied as a preservative-free, sterile, aqueous solution
in a single-use, glass vial designed to deliver 0.05 mL (50 microliters) of
EYLEA (40 mg/mL in 10 mM sodium phosphate, 40 mM sodium chloride, 0.03%
polysorbate 20, and 5% sucrose, pH 6.2).
What are the possible side effects of aflibercept ophthalmic (Eylea)?
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have a serious side effect such as:
- eye pain or redness, swelling around your eyes;
- sudden vision problems;
- seeing flashes of light or "floaters" in your vision;
- eyes being more sensitive to light;
- sudden numbness or weakness, especially on one side of the body; or
- sudden severe headache, confusion, problems with speech or...
Read All Potential Side Effects and See Pictures of Eylea »
Last reviewed on RxList: 10/10/2012
This monograph has been modified to include the generic and brand name in many instances.